VICTORIA, BC, April 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ; , a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery.
Company s Listing Application Approved by Nasdaq
VICTORIA, BC, April 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ; , a clinical-stage biotechnology company leveraging its proprietary.
Eupraxia Pharmaceuticals (EPRX) to Begin Trading on Nasdaq on April 5, 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its.